Impact of belantamab mafodotin–containing regimens on renal function in patients with Relapsed/Refractory multiple myeloma (RRMM) and mild/moderate renal impairment in the dreamm-7 and dreamm-8 trials
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Marcelo Pitombeira de Lacerda, Meletios Dimopoulos, Ludek Pour, Kihyun Kim, Sergei Voloshin, Hanlon Sia, Esther González García, Chang-Ki Min, Anna Sureda Balarí, Ivan Špička, Pawel Robak, Marek Hus, Vera Zherebtsova, Merit Hanna, Vinay Jadhav, Jorge Mouro, Zeyad Khalaf, Nick Pirooz, Ianire Garrobo-Calleja, Lydia Eccersley, Elisabet Manasanch, Vania Hungria, Meral Beksac
Institutions: Universidade da Região de Joinville, Korea University, National and Kapodistrian University of Athens, University Hospital Brno, Samsung Medical Center, Hospital Universitario De Cabueñes, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Universitat de Barcelona, Charles University, Medical University of Lodz, Medical University of Lublin, Botkin Hospital, North Shore Hospital, Waitemata District Health Board, GlaxoSmithKline (Switzerland), GlaxoSmithKline (United States), São Germano Oncologia, Istinye University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108736506
Cites:
Cited by:
Related to: